Becton, Dickinson and Company (BDX) Q1 FY25 earnings call

Becton, Dickinson and Company announced its intent to separate its Biosciences and Diagnostic Solutions business, aiming to unlock value through enhanced strategic focus and targeted capital deployment for both new BD and the separated entity. The company reported strong Q1 FY25 results, exceeding financial goals with robust revenue growth and significant margin expansion, enabling a raise in the midpoint of its full-year adjusted EPS guidance despite increased currency headwinds.